Skip to main content
Equibles
INDV logo

INDV · Indivior Pharmaceuticals, Inc.

Track INDV — free

Use INDV with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INDV

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$39.01 +0.79 (+2.07%) At close · Aug 14
Market Cap
$4.60B
Shares
118.01M

Indivior Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Indivior Pharmaceuticals, Inc. (INDV) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼6.3% $266.00M $47.00M '25 Q1 25-04-24 ▲1% $302.00M $18.00M '25 Q2 25-07-31 ▲2.3% $314.00M $42.00M '25 Q3 25-10-30 ▲19.8% $357.00M $103.00M '25 Q4 26-02-26 ▲19.2% $317.00M $89.00M '26 Q1 26-04-30 LATEST ▲13.6% $343.00M $122.00M '26 Q2 26-08-03
Earnings call
FY26 · Q2
2026-08-03
Q2 2026 Results and Webcast
Revenue
$343.00M
▲ 13.6% YoY
Diluted EPS
$0.98
▲ 600% YoY
Gross margin
85.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Indivior Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone SUBLOCADE U.S. growth 2026 financial guidance raise Pipeline setbacks
Revenue
$317.00M
▲ 19.2% YoY
Diluted EPS
$0.69
▲ 81.6% YoY
Gross margin
87.4%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Indivior Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Revenue
$357.00M*
▲ 19.8% YoY
Gross margin
82.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Indivior Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Revenue
$314.00M
▲ 2.3% YoY
Diluted EPS
$0.33
▲ 106.2% YoY
Gross margin
73.2%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Indivior Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Revenue
$302.00M
▲ 1% YoY
Diluted EPS
$0.14
Gross margin
82.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Indivior Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Revenue
$266.00M
▼ 6.3% YoY
Diluted EPS
$0.38
▼ 15.6% YoY
Gross margin
83.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 317 filings 316 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)